A nurse is caring for a client who has diabetes insipidus and is receiving desmopressin by intermittent IV balus. Which of the fediowing manifestations should indicate to the nurse a therapeutic response to the medication?

A. Increased blood pressure: Heparin does not typically directly affect blood pressure. However, if there are other underlying conditions or complications related to the reason for heparin use, it might indirectly influence blood pressure. But a high aPTT level itself wouldn't directly cause an increase in blood pressure.
B. Decreased temperature: Heparin does not usually affect body temperature. Changes in temperature might occur due to other factors, but they are not directly related to heparin administration or its effects on aPTT.
C. Decreased respiratory rate: Heparin does not typically affect the respiratory rate directly. Changes in respiratory rate might occur due to other causes but are not directly correlated with heparin administration or its effects on aPTT.
D. Increased pulse rate: Heparin, especially when aPTT is elevated, might indicate that the blood is less likely to clot. An increased pulse rate could be indicative of compensatory mechanisms due to potential bleeding or changes in clotting factors influenced by heparin. It's essential to monitor for an increased pulse rate as a potential sign of bleeding complications associated with anticoagulant therapy.

A. Hydromorphone: This is a potent opioid analgesic and is commonly used for the management of severe pain, especially in cancer patients. It provides strong pain relief and is often used in situations where other pain medications are not sufficient.
B. Aspirin: Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory and analgesic properties. While it may be used for pain relief in some situations, it is not typically the first choice for severe pain in pancreatic cancer.
C. Acetaminophen (Caldoler): Acetaminophen is a non-opioid analgesic and antipyretic. It is not as potent as opioids and may not be sufficient for managing severe pain, especially in the context of advanced cancer.

D. Meloxicam: Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) and is not the first-line choice for severe pain, particularly in cancer patients. Opioid analgesics are generally preferred for managing severe pain in cancer.